摘要
考察了索拉非尼(1)合并伊曲康唑(2)在体外对人肺腺癌A549细胞、人肠癌细胞HCT116和人乳腺癌细胞MDA-MB-435的生长抑制作用,及对裸鼠移植A549瘤模型的肿瘤抑制作用。在细胞水平上考察了两药联合作用对人脐静脉内皮细胞(HUVEC)的细胞周期、迁移和管腔形成的作用。再利用小鼠黑素瘤B16转移模型考察了联合用药方案对肺转移的抑制作用。结果表明,1和2联用对体内外抑制肿瘤细胞生长有相加作用。联合用药对抑制HUVEC迁移和管腔形成的作用及将细胞周期阻滞在G0/G1期的作用优于1单用组,并对抑制小鼠黑素瘤肺转移病灶的形成也有相加作用。
The in vitro growth inhibition effects of sorafenib （1） combined with itraconazole （2） on A549 human lung adenocarcinoma cells, HCT 116 human colon cancer cells and MDA-MB-435 human breast cancer cells were investigated. The A549 tumor bearing nude mouse models were adopted to evaluate the in vivo inhibition of the combined regimen. The effects on cell cycle, migration and vessel formation of the human umbilical vein endothelial cells （HUVEC） were also investigated at the cellular level. The inhibition on pulmonary metastasis of the combined regimen was tested with the mice bearing B16 melanoma as the animal models. The additive effects of 1 combined with 2 on the in vitro and in vivo inhibition of tumor cells were observed. The combination treatment could also inhibit the cell cycle progression at the G0/G1 phase and inhibit the migration and vessel formation of HUVEC. The inhibition effect of the combination on HUVEC was superior to 1 alone. The combination of sorafenib with itraconazole also displayed an additive effect on inhibition of pulmonary metastasis of B 16 melanoma tumor.
出处
《中国医药工业杂志》
CAS
CSCD
北大核心
2013年第4期370-375,共6页
Chinese Journal of Pharmaceuticals
关键词
索拉非尼
伊曲康唑
抗肿瘤活性
抑制
管腔生成
转移
sorafenib
itraconazole
antitumor activity
inhibition
vessel formation
metastasis
